Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy (TAMARA)

Pfizer

Status: Completed

Conditions: Breast Neoplasms

Treatments: Other: Aromatase inhibitors

Study type: Observational

Funder types: Industry

Identifiers

NCT00784888

A5991087

Details and patient eligibility

About

The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.

Full description

Group of patients using the same aromatase inhibitor

Enrollment: 344 patients

Sex: Female

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period.

Patients who were informed about the study and accepted to participate.

Exclusion criteria

Patients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and / or patients who are illiterate.

Trial design

344 participants in 1 patient group

Aromatase inhibitors

Description:

Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment

Treatment:

Other: Aromatase inhibitors